Literature DB >> 1781967

Cognitive decline in patients with Alzheimer disease: differences in patients with and without extrapyramidal signs.

T P Miller1, J R Tinklenberg, J O Brooks, J A Yesavage.   

Abstract

We investigated the relationship between extrapyramidal signs (EPSs) in patients diagnosed with Alzheimer disease (AD) and the average rate of decline in different areas of cognition. The presence of tremors, cogwheel rigidity, or bradykinesia were scored as EPS using the California State Department of Health Services AD Diagnostic and Treatment Center Form. Measures of decline were computed by determining patients' average rates of decline on the Mini-Mental State Examination (MMSE). Of the 81 patients, 24 were determined to have EPS not related to medications. Overall, patients with EPS deteriorated 67% faster on MMSE (4.5 points per year) than did patients with no evidence of EPS (2.7 points per year). Our findings indicate that the clinical presence of EPS is a poor overall prognostic sign in patients with a clinical diagnosis of AD.

Entities:  

Mesh:

Year:  1991        PMID: 1781967     DOI: 10.1097/00002093-199100540-00004

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  3 in total

1.  Rapid cognitive decline in Alzheimer's disease. Consensus paper.

Authors:  M E Soto; S Andrieu; C Arbus; M Ceccaldi; P Couratier; T Dantoine; J-F Dartigues; S Gillette-Guyonnet; F Nourhashemi; P-J Ousset; M Poncet; F Portet; J Touchon; B Vellas
Journal:  J Nutr Health Aging       Date:  2008-12       Impact factor: 4.075

2.  Motor signs predict poor outcomes in Alzheimer disease.

Authors:  N Scarmeas; M Albert; J Brandt; D Blacker; G Hadjigeorgiou; A Papadimitriou; B Dubois; M Sarazin; D Wegesin; K Marder; K Bell; L Honig; Y Stern
Journal:  Neurology       Date:  2005-05-24       Impact factor: 9.910

3.  Motor signs during the course of Alzheimer disease.

Authors:  N Scarmeas; G M Hadjigeorgiou; A Papadimitriou; B Dubois; M Sarazin; J Brandt; M Albert; K Marder; K Bell; L S Honig; D Wegesin; Y Stern
Journal:  Neurology       Date:  2004-09-28       Impact factor: 9.910

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.